Alzecure Pharma AB has disclosed UDP-glucuronosyltransferase A1 (UGT1A1; UDPGT 1-1) inhibitors that are potentially useful for the treatment of Lewy body dementia, Creutzfeldt-Jakob disease, frontotemporal dementia, amyotrophic lateral sclerosis, traumatic brain injury, and Parkinson's, Alzheimer's and Huntington's disease, among others.